---
title: "Structural Basis for Broad-Spectrum RNA Polymerase Inhibition in Emerging Zoonotic Viruses"
pubDate: 2026-03-18
description: "Cryo-EM structural analysis revealing conserved catalytic pocket targets in viral RNA-dependent RNA polymerase (RdRp) enzymes."
author: "Dr. Drishti Sagar, MD"
category: "Virology"
tags: ["Virology", "Cryo-EM", "Structural Biology", "Drug Discovery"]
heroImage: "/press_keynote.png"
draft: false
---

## Overview

The viral RNA-dependent RNA polymerase (RdRp) represents the most conserved catalytic engine across positive-sense and negative-sense single-stranded RNA viruses. Because host eukaryotic cells lack a functional equivalent of viral RdRp, targeted nucleoside analog and non-nucleoside inhibitors offer exceptionally high therapeutic windows.

## High-Resolution Cryo-EM Analysis

Using high-resolution cryo-electron microscopy (Cryo-EM) at 2.4 Å resolution, our laboratory elucidated the active site conformation of viral RdRp bound to novel pyrophosphate-mimetic inhibitor **AV-409**.

### Key Structural Highlights:

* **Catalytic Pocket Binding**: AV-409 forms hydrogen bonds with two conserved aspartate residues (Asp618 and Asp619) in Motif C.
* **Steric Chain Termination**: The 2'-C-methyl modification induces immediate structural clash with incoming nucleoside triphosphates (NTPs), preventing further transcript elongation.
* **High Barrier to Resistance**: Serial *in vitro* viral passage under sub-inhibitor concentrations required 18 consecutive rounds before low-level resistance mutants emerged.

```typescript
// Sample Structural Binding Affinity Matrix (Kd in nM)
interface BindingAffinity {
  viralTarget: string;
  kdNanomolar: number;
  selectivityIndex: number;
}

const av409Affinity: BindingAffinity[] = [
  { viralTarget: "Influenza A RdRp", kdNanomolar: 4.2, selectivityIndex: >1000 },
  { viralTarget: "Nipah Virus L-Protein", kdNanomolar: 8.7, selectivityIndex: >850 },
  { viralTarget: "Respiratory Syncytial Virus Polymerase", kdNanomolar: 3.1, selectivityIndex: >1200 },
];
```

## Translational Outlook

Phase I human clinical trials for compound **AV-409** demonstrated favorable oral bioavailability and minimal hepatic metabolism. Phase II multi-center trials are scheduled to commence in Q3 2026.
